Publications by authors named "Yael Mosse"

Claim this Profile
K
Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.
Smita Matkar, Michael P East, Timothy J Stuhlmiller, Gabriela M Witek, Alvin Farrel

Mol Cancer Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.
Steven G DuBois, Lucas Moreno, John Anderson, Shahab Asgharzadeh, Ro Bagatell

Pediatr Blood Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.
Thomas Cash, Araz Marachelian, Steven G DuBois, Yueh-Yun Chi, Anahit Baregamyan, Yael P Mosse

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers.
Alberto D Guerra, Smita Matkar, Christina Acholla, Colleen Casey, Grant Li

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.
John Maris, Isabel Soria-Bretones, Matias Casás-Selves, Minu Samanta, David Groff

Res Sq· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets.
Nathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, Alvin Farrel, Liron Grossmann

Neuro Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study.
Esther R Berko, Arlene Naranjo, Alexander A Daniels, Samantha N McNulty, Kateryna Krytska

J Clin Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anaplastic Lymphoma Kinase Inhibition Therapy for Hereditary Neuroblastoma.
Yaël P Mossé, Grace Polkosnik, Jenny Pogoriler, Peter Mattei, Lisa J States

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma.
Steven G DuBois, Chitose Ogawa, Lucas Moreno, Yaël P Mossé, Matthias Fischer

Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells.
Liron D Grossmann, Chia-Hui Chen, Yasin Uzun, Anusha Thadi, Adam J Wolpaw

Cancer Discov· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons learned from 20 years of preclinical testing in pediatric cancers.
Malcolm A Smith, Peter J Houghton, Richard B Lock, John M Maris, Richard Gorlick

Pharmacol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Amber K Hamilton, Alexander B Radaoui, Matthew Tsang, Daniel Martinez, Karina L Conkrite, Yael P Mosse

Cancer Cell· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Whole genome and reverse protein phase array landscapes of patient derived osteosarcoma xenograft models.
Chia-Chin Wu, Licai Huang, Zhongting Zhang, Zhenlin Ju, Xingzhi Song, Yael Mosse

Sci Rep· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets.
Nathan M Kendsersky, Michal Odrobina, Nathaniel W Mabe, Alvin Farrel, Liron Grossmann

bioRxiv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors.
Eric Lowe, Yael P Mossé

Oncol Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Percutaneous biopsy for the diagnosis, risk stratification, and molecular profiling of neuroblastoma: A single-center retrospective study.
Sean Schoeman, Rochelle Bagatell, Anne Marie Cahill, John Maris, Peter Mattei, Yael Mosse

Pediatr Blood Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Amber K Weiner, Alexander B Radaoui, Matthew Tsang, Daniel Martinez, Simone Sidoli, Yael P Mosse

bioRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi

Nat Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Esther R Berko, Gabriela M Witek, Smita Matkar, Zaritza O Petrova, Megan A Wu

Nat Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lorlatinib use in an infant with thalamic ALK-positive histiocytosis.
Irem Eldem, Jennifer Picarsic, Ashish Kumar, Yaël P Mossé, Kaleigh Filisa Roberts

Pediatr Blood Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Kristopher R Bosse, Anna Maria Giudice, Maria V Lane, Brendan McIntyre, Patrick M Schürch

Cancer Discov· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Kateryna Krytska, Colleen E Casey, Jennifer Pogoriler, Daniel Martinez, Komal S Rathi

Cancer Res Commun· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake.
Andrew Samoyedny, Abhay Srinivasan, Lisa States, Yael P Mosse, Emma Alai

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.
Steven G DuBois, M Meaghan Granger, Susan Groshen, Denice Tsao-Wei, Lingyun Ji, Yael P Mosse

J Clin Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Andrew D J Pearson, Elly Barry, Yael P Mossé, Franca Ligas, Nick Bird

Eur J Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis